192 related articles for article (PubMed ID: 27266545)
1. Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.
Lu S; Zhang J; Ye M; Wang B; Wu B
Pharmacogenomics; 2016 Jun; 17(9):985-94. PubMed ID: 27266545
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
3. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
Lee JA; Bubendorf L; Stahel R; Peters S
Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
Lu S; Yu Y; Fu S; Ren H
PLoS One; 2018; 13(10):e0205827. PubMed ID: 30352060
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
[TBL] [Abstract][Full Text] [Related]
6. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib and testing for ALK.
Shaw AT; Solomon B; Kenudson MM
J Natl Compr Canc Netw; 2011 Dec; 9(12):1335-41. PubMed ID: 22157554
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
[TBL] [Abstract][Full Text] [Related]
9. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
10. Treatment and detection of ALK-rearranged NSCLC.
Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
12. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
Yi ES; Chung JH; Kulig K; Kerr KM
Mol Diagn Ther; 2012 Jun; 16(3):143-50. PubMed ID: 22506598
[TBL] [Abstract][Full Text] [Related]
13. Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
J Clin Oncol; 2016 Oct; 34(28):3383-9. PubMed ID: 27354483
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
15. [ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].
Audigier-Valette C; Girard N; Cortot AB; Mennecier B; Debieuvre D; Planchard D; Zalcman G; Moro-Sibilot D; Cadranel J; Barlesi F
Bull Cancer; 2014 Sep; 101(9):823-31. PubMed ID: 25299566
[TBL] [Abstract][Full Text] [Related]
16. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
Cameron L; Solomon B
Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
Di Maio M; De Marinis F; Hirsch FR; Gridelli C
Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
[TBL] [Abstract][Full Text] [Related]
18. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
Giroux Leprieur E; Wislez M
Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
[No Abstract] [Full Text] [Related]
19. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
20. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
Ren S; Hirsch FR; Varella-Garcia M; Aisner DL; Boyle T; Zhou C; Camidge DR
J Thorac Oncol; 2014 Mar; 9(3):e21-3. PubMed ID: 24518095
[No Abstract] [Full Text] [Related]
[Next] [New Search]
